← Back to Clinical Trials
Recruiting NCT06588101

NCT06588101 Clinical Trial Recruitment and Retention Strategies for Family Members in the ICU

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06588101
Status Recruiting
Phase
Sponsor Lady Davis Institute
Condition Family Members
Study Type INTERVENTIONAL
Enrollment 160 participants
Start Date 2024-05-01
Primary Completion 2026-04-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Written informed consent with infographicCompensation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 160 participants in total. It began in 2024-05-01 with a primary completion date of 2026-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

There is a need to identify strategies that improve the conduct of clinical trials involving family members of intensive care unit (ICU) patients. The purpose of the present study is to evaluate recruitment and retention strategies for clinical trials involving family members of ICU patients. 4 strategies (2 recruitment and 2 retention) will be tested. Investigators will integrate the strategies into three existing studies that involve family members of ICU patients. Participants will be randomized using a 2x2 factorial design. The co-primary outcomes are recruitment percentage (participants enrolled/participants approached) and retention percentage (participants completing follow-up/participants enrolled).

Eligibility Criteria

Inclusion Criteria: * Has family member admitted to an intensive care unit. * Expected hospital stay \> 48 hours * Able to participate in English or French Exclusion Criteria: * Has another family member participating in the trial * Repeat admissions within the study period

Contact & Investigator

Central Contact

Jillian Kifell, MSc

✉ jillian.kifell.ccomtl@ssss.gouv.qc.ca

📞 5143408222

Principal Investigator

Michael J Goldfarb, MD, MSc

PRINCIPAL INVESTIGATOR

Lady Davis Institute, McGill University, Jewish General Hospital

Frequently Asked Questions

Who can join the NCT06588101 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Family Members. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06588101 currently recruiting?

Yes, NCT06588101 is actively recruiting participants. Contact the research team at jillian.kifell.ccomtl@ssss.gouv.qc.ca for enrollment information.

Where is the NCT06588101 trial being conducted?

This trial is being conducted at Montreal, Canada.

Who is sponsoring the NCT06588101 clinical trial?

NCT06588101 is sponsored by Lady Davis Institute. The principal investigator is Michael J Goldfarb, MD, MSc at Lady Davis Institute, McGill University, Jewish General Hospital. The trial plans to enroll 160 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology